Reduction of the share capital and holding of own shares (19 June
2007)
At Novo Nordisk's ordinary general meeting on the 7 March 2007 it was
decided to reduce the company's B-share capital from DKK 566,432,800
to DKK 539,472,800 by cancellation of part of the company's portfolio
of own B shares at a nominal value of DKK 26,960,000 divided into
13,480,000 B shares of DKK 2 each.
Today, Novo Nordisk has registered the final implementation of the
reduction of the share capital with the Danish Commerce and Companies
Agency and cancelled nominally DKK 26,960,000 B shares. After the
reduction of the share capital, the company's share capital is
nominally DKK 646,960,000, which is divided into an A share capital
of nominally DKK 107,487,200 and a B share capital of nominally DKK
539,472,800.
Holding of own shares
In the company's stock exchange announcement no 8/2007 of 3 April
2007 it was stated that Novo Nordisk A/S (NYSE: NVO) and its
wholly-owned affiliates as per 31 March 2007 owned 19,163,309 of its
own B shares of DKK 2, corresponding to a total nominal value of DKK
38,326,618 or 5.69% of the total share capital.
Since 3 April 2007 a total of 138,000 B shares have been repurchased
by Novo Nordisk A/S, and 306,625 B shares have been disposed of to
employees who have exercised options granted by Novo Nordisk.
Following the cancellation of nominally DKK 26,960,000 (13,480,000
shares) of the company's own B shares and pursuant to Section 28 of
the Danish securities Trading Act, it is hereby announced that Novo
Nordisk A/S and its wholly-owned affiliates as per 19 June 2007 own
5,514,684 of its own B shares. This corresponds to a total nominal
value of DKK 11,029,368 B-shares or 1.7% of the total share capital.
Novo Nordisk is a healthcare company and a world leader in diabetes
care. The company has the broadest diabetes product portfolio in the
industry, including the most advanced products within the area of
insulin delivery systems. In addition, Novo Nordisk has a leading
position within areas such as haemostasis management, growth hormone
therapy and hormone replacement therapy. Novo Nordisk manufactures
and markets pharmaceutical products and services that make a
significant difference to patients, the medical profession and
society. With headquarters in Denmark, Novo Nordisk employs
approximately 23.600 full-time employees in 79 countries, and markets
its products in 179 countries. Novo Nordisk's B shares are listed on
the stock exchanges in Copenhagen and London. Its ADRs are listed on
the New York Stock Exchange under the symbol 'NVO'. For more
information, visit novonordisk.com.
Further information:
Media: Investors:
Outside North America: Outside North America:
Elin K Hansen Mads Veggerby Lausten
Tel: (+45) 4442 3450 Tel: (+45) 4443 7919
ekh@novonordisk.com mlau@novonordisk.com
Hans Rommer
Tel: (+45) 4442 4765
hrmm@novonordisk.com
In North America: In North America:
Lori Moore Christian Qvist Frandsen
Tel: (+1) 609 919 7991 Tel: (+1) 609 919 7937
lrmo@novonordisk.com cqfr@novonordisk.com
Stock Exchange Announcement no 16 / 2007